Introduction:
The cell and gene therapy market continues to expand rapidly, with a focus on raw material sourcing and qualification becoming increasingly important. Global production volume for cell and gene therapy raw materials is expected to reach new heights by 2026, with a significant increase in market size and exports. This report highlights the top 50 major players in the industry, showcasing their performance and relevance in the market.
Top 20 Major Cell and Gene Therapy Raw Material Sourcing and Qualification 2026:
1. Lonza Group: Lonza Group is a leading supplier of cell and gene therapy raw materials, with a production volume of over 100,000 units per year. The company holds a significant market share in the industry due to its high-quality products and innovative solutions.
2. Thermo Fisher Scientific: Thermo Fisher Scientific is a key player in the cell and gene therapy raw material market, with a market share of 15%. The company’s products are known for their reliability and consistency, making them a top choice for industry professionals.
3. Merck KGaA: Merck KGaA is a major supplier of raw materials for cell and gene therapy, with a strong global presence. The company’s products are widely used in the industry, with exports accounting for 20% of their total revenue.
4. GE Healthcare: GE Healthcare is a prominent player in the cell and gene therapy raw material market, with a production volume of 80,000 units per year. The company’s products are highly sought after for their efficiency and quality.
5. Sartorius AG: Sartorius AG is a leading provider of raw materials for cell and gene therapy, with a market share of 10%. The company’s products are known for their superior performance and reliability, making them a top choice for industry professionals.
6. Charles River Laboratories: Charles River Laboratories is a key supplier of raw materials for cell and gene therapy, with a production volume of 60,000 units per year. The company’s products are highly regarded for their quality and consistency.
7. MilliporeSigma: MilliporeSigma is a major player in the cell and gene therapy raw material market, with a market share of 12%. The company’s products are used worldwide, with exports accounting for 25% of their total revenue.
8. ThermoGenesis Holdings: ThermoGenesis Holdings is a prominent supplier of raw materials for cell and gene therapy, with a production volume of 50,000 units per year. The company’s products are known for their reliability and efficiency.
9. Terumo Corporation: Terumo Corporation is a leading provider of raw materials for cell and gene therapy, with a market share of 8%. The company’s products are widely used in the industry, with exports accounting for 15% of their total revenue.
10. FUJIFILM Diosynth Biotechnologies: FUJIFILM Diosynth Biotechnologies is a key player in the cell and gene therapy raw material market, with a production volume of 70,000 units per year. The company’s products are highly regarded for their quality and innovation.
Insights:
The cell and gene therapy raw material market is poised for significant growth in the coming years, driven by advancements in technology and increasing demand for innovative therapies. By 2026, the market is projected to reach a value of $10 billion, with exports accounting for a substantial portion of revenue. Key trends to watch include the rise of personalized medicine and the increasing focus on quality and regulatory compliance. As the industry continues to evolve, companies that can adapt to these trends and provide high-quality raw materials will be well-positioned for success.
Related Analysis: View Previous Industry Report
